Data Supplement
- Supplemental Data -
Supplemental Table 1- Quantitation of MMAE, and DMx (DM1, DM3, and DM4) and associated methylated metabolites (methylated DMx, DM-Me) in tumors of xenograft mice following intravenously administration of corresponding ADC conjugates.
Supplemental Table 2 - Quantitation of total antibody (Tab) in plasma of xenograft mice following intravenously administration of corresponding ADC conjugates.
Supplemental Figure 1 - Correlation (X-Y plots) of tumor growth inhibition with intratumor DMx (DM+DM-Me) in mice bearing human CD22-expressing BJAB.Luc xenografts.
Supplemental Figure 2 - Body weights from In vivo efficacy studies of PBD-, MMAE-, and DMx-ADCs in mice bearing human HER2-expressing Fo5 or human CD22-expressing BJAB.Luc xenografts (n = 8) after intravenous administration of corresponding ADCs A1-A4 (I), B1-B4 (II), C1-C8 (III), and D1-3 (IV, V, VI).
Supplemental Figure 3 - Correlation analysis of tumor growth inhibition with intratumor MMAE concentrations from Conjugates B1-B4 in mice bearing human CD22-expressing BJAB.Luc xenografts.
Supplemental Figure 4 - Correlation analysis of tumor growth inhibition with intratumor DMx-Me concentrations from Conjugates C1-C8 in mice bearing human CD22-expressing BJAB.Luc xenografts.